%0 Journal Article
%A Galldiks, N.
%A Stoffels, G.
%A Filss, C.
%A Rapp, M.
%A Blau, T.
%A Tscherpel, C.
%A Ceccon, G.
%A Dunkl, V.
%A Weinzierl, M.
%A Stoffel, M.
%A Sabel, M.
%A Fink, G. R.
%A Shah, N. J.
%A Langen, K.-J.
%T The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma
%J Neuro-Oncology
%V 17
%N 9
%@ 1523-5866
%C Oxford
%I Oxford Univ. Press
%M FZJ-2015-05820
%P 1293-1300
%D 2015
%X Background We evaluated the diagnostic value of static and dynamic O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET) PET parameters in patients with progressive or recurrent glioma.Methods We retrospectively analyzed 132 dynamic 18F-FET PET and conventional MRI scans of 124 glioma patients (primary World Health Organization grade II, n = 55; grade III, n = 19; grade IV, n = 50; mean age, 52 ± 14 y). Patients had been referred for PET assessment with clinical signs and/or MRI findings suggestive of tumor progression or recurrence based on Response Assessment in Neuro-Oncology criteria. Maximum and mean tumor/brain ratios of 18F-FET uptake were determined (20–40 min post-injection) as well as tracer uptake kinetics (ie, time to peak and patterns of the time–activity curves). Diagnoses were confirmed histologically (95%) or by clinical follow-up (5%). Diagnostic accuracies of PET and MR parameters for the detection of tumor progression or recurrence were evaluated by receiver operating characteristic analyses/chi-square test.Results Tumor progression or recurrence could be diagnosed in 121 of 132 cases (92%). MRI and 18F-FET PET findings were concordant in 84% and discordant in 16%. Compared with the diagnostic accuracy of conventional MRI to diagnose tumor progression or recurrence (85%), a higher accuracy (93%) was achieved by 18F-FET PET when a mean tumor/brain ratio ≥2.0 or time to peak <45 min was present (sensitivity, 93%; specificity, 100%; accuracy, 93%; positive predictive value, 100%; P < .001).Conclusion Static and dynamic 18F-FET PET parameters differentiate progressive or recurrent glioma from treatment-related nonneoplastic changes with higher accuracy than conventional MRI.
%F PUB:(DE-HGF)16
%9 Journal Article
%U <Go to ISI:>//WOS:000361306400015
%$ pmid:26008606
%R 10.1093/neuonc/nov088
%U https://juser.fz-juelich.de/record/255687